Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 439,71 € (+8,76 %). La mediana es de 453,43 € (+12,15 %).
| Comprar |
40 |
| Mantener |
12 |
| Vender |
5 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Intuitive Surgical impresses with quarterly results and offers further upside potential
Intuitive Surgical reported third-quarter revenue growth of 22% and an increase in procedures of about 15%. Analysts see tailwinds from the new da Vinci 5 and sustained demand in parts of Europe; Baird raised its price target to $550. The stock shows relative strength, is poised to break above $458, and market experts attribute roughly 25% more upside to the shares. » Más en deraktionaer.de
Intuitive Surgical back at yearly high after Q3 numbers – stock rebounds after sell-off
Intuitive Surgical beat revenue and earnings expectations in the third quarter, pushing the share price back up after a temporary pullback of around ten percent. The stock outperformed the market and briefly reached its highest level since May, sustainably breaking above the 200-day moving average. Analysts view the pullback as a buying opportunity despite concerns about comparison effects and growth worries in the U.S. » Más en deraktionaer.de
Intuitive Surgical beats expectations, stock falls after $450m settlement
Intuitive Surgical reported third-quarter revenue up 22% to $3.05 billion and adjusted earnings per share of $3.00, both well above analysts’ estimates. Procedures using surgical robots rose 15% and the installed base of Da‑Vinci systems topped 12,000 units for the first time. Despite the strong results, the stock sank by just over ten percent at one point after the company said it will pay a $450 million settlement. Intuitive holds $6.8 billion in cash and announced share buybacks of about $2.94 billion. » Más en deraktionaer.de
Intuitive Surgical ahead of quarterly results: US procedures and guidance in focus
Intuitive Surgical will report third-quarter results on Tuesday after the US market close. Analysts expect revenue of $2.91 billion and adjusted earnings per share of $2.65. Key for the stock is whether management classifies the slowed growth in Da Vinci procedures in the US as temporary and raises the full-year guidance; the shares are currently about 30% below their 52-week high and just under the 200-day moving average. Competitive pressure from Stryker and CMR Surgical is cited as an additional risk factor. » Más en deraktionaer.de
Intuitive Surgical: growth slows, outlook remains confirmed
At the Wells‑Fargo conference, Intuitive Surgical reported a slowdown in growth of U.S. procedure volumes but reaffirmed its guidance for global procedure growth of 13.5–15.5% and expects results near the midpoint. The company reported robust revenue, margin and free‑cash‑flow growth in the first half and highlighted support from system upgrades, the launch of the da Vinci 5, expansion into ambulatory surgery centers, and AI and software offerings. Competitive pressure from new market entrants and challenges in China, as well as a decline in bariatric procedures, are cited as headwinds; the operating margin target remains 35–40% and significant share buybacks have been carried out. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 2691,55 M | 26,09 % |
| Beneficio bruto | 1840,12 M | 29,90 % |
| Beneficio neto | 461,55 M | 23,11 % |
| EBITDA | 590,1 M | 31,79 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 139,45 mil M € |
Número de acciones | 346,64 M |
Máximo/mínimo de 52 semanas | 547,63 € - 297,97 € |
| Dividendos | No |
Beta | 1,44 |
Ratio P/E | 53,00 |
Ratio PEG | 5,99 |
Ratio P/B | 9,68 |
Ratio P/S | 13,28 |
Perfil de la empresa
Intuitive Surgical, Inc. desarrolla, fabrica y comercializa productos que permiten a los médicos y a los proveedores de atención sanitaria mejorar la calidad y el acceso a la atención mínimamente invasiva en Estados Unidos y a nivel internacional. La compañía ofrece el sistema quirúrgico da Vinci, que permite realizar cirugías complejas mediante un enfoque mínimamente invasivo; y el sistema endoluminal Ion, que amplía su oferta comercial más allá de la cirugía hacia procedimientos de diagnóstico que permiten realizar biopsias mínimamente invasivas en el pulmón. También proporciona un conjunto de instrumentos de grapado, energía e instrumentación básica para sus sistemas quirúrgicos; itinerarios de aprendizaje progresivo para respaldar el uso de su tecnología; una gama de servicios para sus clientes, que incluye soporte, instalación, reparación y mantenimiento; y capacidades digitales integradas que ofrecen soluciones unificadas y conectadas, optimizando el rendimiento de los hospitales con información que mejora los programas. La compañía se constituyó en 1995 y tiene su sede en Sunnyvale, California.
| Nombre | Intuitive Surgical |
| CEO | David J. Rosa |
| Sede | Sunnyvale,
ca Estados Unidos |
| Sitio web | |
| Sector | Salud |
| Industria | Tecnología sanitaria |
| Salida a bolsa | 10/08/2023 |
| Empleados | 17.021 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | ISRG |
London Stock Exchange | 0R29.L |
XETRA | IUI1.DE |
Frankfurt | IUI1.F |
Düsseldorf | IUI1.DU |
Hamburg | IUI1.HM |
Milan | 1ISRG.MI |
London | 0R29.L |
SIX | ISRG.SW |
München | IUI1.MU |
Wien | ISRG.VI |